Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 30;16(9):e70498.
doi: 10.7759/cureus.70498. eCollection 2024 Sep.

Efficacy and Safety of Mometasone Furoate Nasal Spray in Treating Nasal Polyposis: A Systematic Review and Meta-Analysis

Osamah H Mohya  1 , Alaa A Alghamdi  2 , Alanoud A Alomar  3 , Amal M Alharbi  4 , Amal M Ageeli  5 , Danah H Alharbi  2 , Haya M Alotaibi  6 , Manar S Alghamdi  7 , Marya A Alkhamis  8 , Moath H Shawosh  7 , Renad S Alayidh  9 , Salma A Binmahfoodh  2 , Shahad M Albariqi  1 , Hadi Afandi Al-Hakami  10 , Mohammed Al-Garni  11
Affiliations
Review

Efficacy and Safety of Mometasone Furoate Nasal Spray in Treating Nasal Polyposis: A Systematic Review and Meta-Analysis

Osamah H Mohya et al. Cureus. .

Abstract

Topical and systemic corticosteroids are the most effective medical treatment for nasal polyps, this study aims to systematically explore the efficacy and safety of mometasone furoate (MTF) for patients with nasal polyps (NP). The systematic review was conducted following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines and was registered in The International Prospective Register of Systematic Reviews (PROSPERO.) Data were extracted from relevant and appropriate randomized controlled trials (RCTs) of synthetic corticosteroids for patients with nasal polyps from PubMed, Google Scholar, Web of Science, and Science Direct, encompassing studies published between January 1995 and July 2024. A total of 834 publications were found based on the search criteria. Around 1,710 patients were reviewed for this systematic review from full full-text articles. Primary outcomes include a change in polyp size (assessed by total polyp size scores), and nasal congestion (assessed by measuring changes from baseline in nasal congestion/obstruction scores). secondary outcomes consist of nasal symptoms, including loss of smell, anterior rhinorrhea, postnasal drip, quality of life outcomes, and adverse events. Mometasone furoate nasal spray (MFNS) significantly improves nasal symptoms and reduces nasal polyp size for patients with nasal polyps (NP).

Keywords: efficacy; mometasone furoate; nasal polyps; randomized controlled trials; safety.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Flow Diagram of Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Figure 2
Figure 2. Forest Plot of the Risk Ratio for Subjects With an Improvement With MFNS Once Daily Compared to Placebo
[11-13], MFNS: mometasone furoate nasal spray.
Figure 3
Figure 3. Forest Plot of the Risk Ratio for Subjects With an Improvement With MFNS Twice Daily Compared to Placebo
[11,13,14], MFNS: mometasone furoate nasal spray.
See this image and copyright information in PMC

References

    1. A review of nasal polyposis. Newton JR, Ah-See KW. Ther Clin Risk Manag. 2008;4:507–512. - PMC - PubMed
    1. An update on the diagnosis and treatment of sinusitis and nasal polyposis. Bachert C, Hörmann K, Mösges R, et al. Allergy. 2003;58:176–191. - PubMed
    1. Evaluation on quality of life in patients with nasal polyposis managed with optimal medical therapy. Aboud SK, Husain S, Gendeh BS. Allergy Rhinol (Providence) 2014;5:2–8. - PMC - PubMed
    1. Nasal polyps treatment: medical management. Mygind N, Lildholdt T. Allergy Asthma Proc. 1996;17:275–282. - PubMed
    1. A randomized controlled trial showing efficacy of once daily intranasal budesonide in nasal polyposis. Filiaci F, Passali D, Puxeddu R, Schrewelius C. https://pubmed.ncbi.nlm.nih.gov/11190754/ Rhinology. 2000;38:185–190. - PubMed

LinkOut - more resources